Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919176 · ClinicalTrials.gov registry record · Early Phase 1
Brown Fat Activation Study
A Early Phase 1 study, sponsored by Philip Kern.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT02919176 is a Early Phase 1 study that has completed, run by Philip Kern. The registered enrollment target is 39 participants.
The verdict
NCT02919176, a Early Phase 1 study, has completed, sponsored by Philip Kern.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open lable, pilot study in which the investigator will research the effect of two FDA approved drugs, Mirabegron and Pioglitazone on fat tissue. Pioglitazone is drug approved by the FDA for the treatment of diabetes and Mirabegron is a drug that is approved by the FDA for the treatment of overactive bladder. These drugs are not approved by the FDA for the purposes being studied in this research. Therefore, the way in which the investigator intends to use them in this study are considered investigational.
Interventions
- DRUG Pioglitazone
- DRUG Mirabegron
- DRUG Mirabegron and Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2019-02-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02919176
The ClinicalTrials.gov registry entry for NCT02919176 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philip Kern, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pioglitazone is the first listed.
NCT02919176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02919176 about?
NCT02919176 is a clinical study titled "Brown Fat Activation Study". This is an open lable, pilot study in which the investigator will research the effect of two FDA approved drugs, Mirabegron and Pioglitazone on fat tissue. Pioglitazone is drug approved by the FDA for the treatment of diabetes and Mirabegron is a drug that is approved by the FDA for the treatment o...
What is the current status of trial NCT02919176?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2016-09-01. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT02919176?
The interventions under investigation include: Pioglitazone (DRUG), Mirabegron (DRUG), Mirabegron and Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT02919176?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.